NEWEST TO THE MARKET (FDA Drug Approvals)

  • Polivy (polatuzumab vedotin-piiq) – To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma

          Approval Date: 10 June 2019

—————————————————————————————————————————————————————————————————————————————

  • Piqray (alpelisib) – To treat breast cancer

          Approval Date: 24 May 2019

—————————————————————————————————————————————————————————————————————————————

  • Vyndaqel  (tafamidis meglumine) –  To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.

          Approval Date:  3 May 2019

—————————————————————————————————————————————————————————————————————————————

  • Skyrizi  (risankizumab-rzaa) –  To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.  

          Approval Date:  23 Apr 2019

—————————————————————————————————————————————————————————————————————————————

  • Balversa  (erdafitinib) –  To treat adult patients with locally advanced or metastatic bladder cancer.

          Approval Date:  12  Apr 2019

—————————————————————————————————————————————————————————————————————————————

  • Evenity  (romosozumab-aqqg)  –  To treat osteoporosis in postmenopausal women at high risk of fracture.

          Approval Date:  9 Apr 2019

—————————————————————————————————————————————————————————————————————————————

  • Mayzent  (siponimod)  –  To treat adults with relapsing forms of multiple sclerosis.

          Approval Date:  26 Mar 2019

—————————————————————————————————————————————————————————————————————————————

  • Sunosi  (solriamfetol) –  To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

          Approval Date:  20 Mar 2019

—————————————————————————————————————————————————————————————————————————————

  • Zulresso  (brexanolone) –  To treat postpartum depression (PPD) in adult women.

          Approval Date:  19 Mar 2019

—————————————————————————————————————————————————————————————————————————————

  • Egaten  (triclabendazole)-  To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”.

          Approval Date:  13 Feb 2019

—————————————————————————————————————————————————————————————————————————————

  • Cablivi (caplacizumab-yhdp) – To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).

          Approval Date:  6 Feb 2019

—————————————————————————————————————————————————————————————————————————————

  • Jeuveau (prabotulinumtoxinA-xvfs) – For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

          Approval Date:  1 Feb 2019